EcoDrugPlus

Dna Topoisomerase I

Ensembl ID : ENSMZEG00005026581
Gene Symbol: TOP1
3 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSMZEG00005009940
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSMZEG00005017395
Gene Symbol: TOP2B
3 Cross references
207 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSMZEG00005018270
Gene Symbol: EML4
2 Cross references
207 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSMZEG00005010699
Gene Symbol: EPHA3
3 Cross references
210 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSMZEG00005022043
Gene Symbol: F2RL3
1 Cross references
195 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSMZEG00005012085
Gene Symbol: FAU
3 Cross references
300 Possible Orthologues:

Fyn Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMZEG00005015722
Gene Symbol: FYN
3 Cross references
196 Possible Orthologues:

G Protein-Coupled Receptor 119

Ensembl ID : ENSMZEG00005011792
Gene Symbol: GPR119
4 Cross references
174 Possible Orthologues:

G-Protein Coupled Receptor 84

Ensembl ID : ENSMZEG00005008264
Gene Symbol: LOC101480161
3 Cross references
113 Possible Orthologues:

Hck Proto-Oncogene, Src Family Tyrosine Kinase

Ensembl ID : ENSMZEG00005022146
Gene Symbol: HCK
3 Cross references
202 Possible Orthologues:

Il2 Inducible T Cell Kinase

Ensembl ID : ENSMZEG00005008029
Gene Symbol: ITK
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).